Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Jens Holstein Biography and Net Worth

Director of Veracyte

Jens Holstein has 25 years of financial and management expertise, spanning an array of global life science businesses. In 2011, Mr. Holstein was appointed Chief Financial Officer of MorphoSys, a clinical-stage biopharmaceutical company based in Munich, Germany. Before joining MorphoSys, Mr. Holstein worked at the pharmaceutical company Fresenius Kabi AG, a subsidiary of Fresenius SE, as Regional Chief Financial Officer for the Europe/Middle East Region and as Managing Director of Fresenius Kabi Deutschland GmbH. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein held multiple other leadership positions within the Fresenius SE Group including Managing Director of Fresenius ProServe GmbH and Chief Financial Officer and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects and Service business unit of Fresenius, and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry. He holds a Diploma in Business Administration from the University of Münster (Germany).

What is Jens Holstein's net worth?: The estimated net worth of Jens Holstein is at least $1.09 million as of August 7th, 2024. Mr. Holstein owns 27,878 shares of Veracyte stock worth more than $1,092,818 as of November 20th. This net worth evaluation does not reflect any other assets that Mr. Holstein may own. Learn More about Jens Holstein's net worth.
How do I contact Jens Holstein?: The corporate mailing address for Mr. Holstein and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected]. Learn More on Jens Holstein's contact information.
Has Jens Holstein been buying or selling shares of Veracyte?: Jens Holstein has not been actively trading shares of Veracyte during the last ninety days. Most recently, Jens Holstein sold 5,000 shares of the business's stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $29.00, for a transaction totalling $145,000.00. Following the completion of the sale, the director now directly owns 27,878 shares of the company's stock, valued at $808,462. Learn More on Jens Holstein's trading history.
Who are Veracyte's active insiders?: Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Karin Eastham (Director), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), and Marc Stapley (CEO & Director ). Learn More on Veracyte's active insiders.
Are insiders buying or selling shares of Veracyte?: In the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 63,827 shares worth more than $1,779,423.17. The most recent insider tranaction occured on September, 19th when Director Evan/ Fa Jones sold 5,173 shares worth more than $182,244.79. Insiders at Veracyte own 1.3% of the company. Learn More about insider trades at Veracyte.
Information on this page was last updated on 9/19/2024.

Jens Holstein Insider Trading History at Veracyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/7/2024	Sell	5,000	$29.00	$145,000.00	27,878
6/14/2022	Sell	8,720	$16.27	$141,874.40	2,000
6/3/2021	Buy	2,000	$35.19	$70,380.00	2,000

Jens Holstein Buying and Selling Activity at Veracyte

Veracyte Company Overview

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Today's Range

Now: $39.20

$38.61

$39.80

50 Day Range

MA: $34.40

$30.32

$39.53

2 Week Range

Now: $39.20

$18.61

$41.43

Volume

631,390 shs

Average Volume

871,517 shs

Market Capitalization

$3.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

This company will win the AI race

From Porter & Company | Ad